The occurrence of lymphoma during the use of a PD-1 inhibitor may be related to the fact that the patient’s lymphoma was a highly invasive NHL as well as to some genetic features such as chromosome 9p24.1 changes and PD-L1 expression. The gene discussed is PDCD1; the disease is non-Hodgkin lymphoma.